Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published October 16, 2023 | Submitted
Discussion Paper Open

The Interferon-inducible NAMPT acts as a protein phosphoribosylase to restrict viral infection

Abstract

As obligate intracellular pathogens, viruses often activate host metabolic enzymes to supply intermediates that support progeny production. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the salvage NAD+ synthesis, is an interferon-inducible protein that inhibits the replication of several RNA and DNA viruses with unknown mechanism. Here we report that NAMPT restricts herpes simplex virus 1 (HSV-1) replication via phosphoribosyl-hydrolase activity toward key viral structural proteins, independent of NAD+ synthesis. Deep mining of enriched phosphopeptides of HSV-1-infected cells identified phosphoribosylated viral structural proteins, particularly glycoproteins and tegument proteins. Indeed, NAMPT de-phosphoribosylates viral proteins in vitro and in cells. Chimeric and recombinant HSV-1 carrying phosphoribosylation-resistant mutations show that phosphoribosylation promotes the incorporation of structural proteins into HSV-1 virions and subsequent virus entry. Moreover, loss of NAMPT renders mice highly susceptible to HSV-1 infection. The work describes a hidden enzyme activity of a metabolic enzyme in viral infection and host defense, offering a system to interrogate roles of phosphoribosylation in metazoans.

Copyright and License

 

Acknowledgement

Acknowledgements. We thank Dr. Shin-Ichiro Imai (Washington University) for providing the Namptfl/flmice, Dr. Jon Hao (Poochon Scientific) for proteomics analysis, Dr. Wandy Beatty (Washington University) for electron microscopy analysis, Drs. Weiming Yuan (University of Southern California), David Knipe (Harvard Medical School) and Richard Longnecker (Northwestern University) for providing HSV-1 plasmids, Dr. Jun Zhao (Cleveland Clinic Foundation) for guidance on generating HSV-1 mutant viruses, Dr. Gary Cohen (University of Pennsylvania) for anti-gH antibody, Dr. Chunfu Zhen (University of Calgary) for anti-VP22 antibody, and Mr. Brett Lomenick (CalTech) for processing MS samples. We are grateful to Yuzheng Zhou, Stephanie Rice, Drs. Jessica Carriere and Jun Xiao for their assistance. This work was partly supported by a startup fund from the Herman Ostrow School of Dentistry of USC and grants from NIH (AG070904, CA285192 and AI180537) and Infectious Disease Society of America Foundation (Microbial Pathogenesis in AD).

Contributions

Conceptualization: PF, SZ, QC; Methodology: SZ, NX, YL, QC, TW, PF, TC; Investigation: SZ, NX, YL, QC, ACS, TW, YR, SL, AS; Funding acquisition: PF, CB; Project administration: PF, CH; Supervision: PF, CB, CH, TC; Writing – original draft: PF, SZ; Writing – review & editing: PF, SZ, CB, CQ.

Conflict of Interest

CB is a chief scientific advisor of ChromaDex and co-founder of Alphina Therapeutics. PF is a consultant for Marc J Bern & Partners. All other authors declare no competing interests.

Files

2023.10.12.562112v1.full.pdf
Files (10.0 MB)
Name Size Download all
md5:4b746534181f4010a599193e423f0752
4.0 MB Preview Download
md5:2e4177f4c7cd3cf32f3b1d170dcfdf49
6.0 MB Preview Download

Additional details

Created:
June 17, 2024
Modified:
June 17, 2024